204 related articles for article (PubMed ID: 10360646)
1. Loss of DNA mismatch repair facilitates reactivation of a reporter plasmid damaged by cisplatin.
Cenni B; Kim HK; Bubley GJ; Aebi S; Fink D; Teicher BA; Howell SB; Christen RD
Br J Cancer; 1999 May; 80(5-6):699-704. PubMed ID: 10360646
[TBL] [Abstract][Full Text] [Related]
2. P53 modulates the effect of loss of DNA mismatch repair on the sensitivity of human colon cancer cells to the cytotoxic and mutagenic effects of cisplatin.
Lin X; Ramamurthi K; Mishima M; Kondo A; Christen RD; Howell SB
Cancer Res; 2001 Feb; 61(4):1508-16. PubMed ID: 11245458
[TBL] [Abstract][Full Text] [Related]
3. DNA polymerase zeta accounts for the reduced cytotoxicity and enhanced mutagenicity of cisplatin in human colon carcinoma cells that have lost DNA mismatch repair.
Lin X; Trang J; Okuda T; Howell SB
Clin Cancer Res; 2006 Jan; 12(2):563-8. PubMed ID: 16428501
[TBL] [Abstract][Full Text] [Related]
4. A combination of MSH2 DNA mismatch repair deficiency and expression of the SV40 large T antigen results in cisplatin resistance of mouse embryonic fibroblasts.
Yasin SL; Rainbow AJ
Int J Oncol; 2011 Sep; 39(3):719-26. PubMed ID: 21667017
[TBL] [Abstract][Full Text] [Related]
5. Hypoxia-induced enrichment and mutagenesis of cells that have lost DNA mismatch repair.
Kondo A; Safaei R; Mishima M; Niedner H; Lin X; Howell SB
Cancer Res; 2001 Oct; 61(20):7603-7. PubMed ID: 11606400
[TBL] [Abstract][Full Text] [Related]
6. In vitro and in vivo resistance to cisplatin in cells that have lost DNA mismatch repair.
Fink D; Zheng H; Nebel S; Norris PS; Aebi S; Lin TP; Nehmé A; Christen RD; Haas M; MacLeod CL; Howell SB
Cancer Res; 1997 May; 57(10):1841-5. PubMed ID: 9157971
[TBL] [Abstract][Full Text] [Related]
7. Elevated DNA repair capacity is associated with intrinsic resistance of lung cancer to chemotherapy.
Zeng-Rong N; Paterson J; Alpert L; Tsao MS; Viallet J; Alaoui-Jamali MA
Cancer Res; 1995 Nov; 55(21):4760-4. PubMed ID: 7585500
[TBL] [Abstract][Full Text] [Related]
8. Role of the mismatch repair system and p53 in the clastogenicity and cytotoxicity induced by bleomycin.
Vernole P; Tedeschi B; Tentori L; Levati L; Argentin G; Cicchetti R; Forini O; Graziani G; D'Atri S
Mutat Res; 2006 Feb; 594(1-2):63-77. PubMed ID: 16139849
[TBL] [Abstract][Full Text] [Related]
9. Effects of camptothecin on double-strand break repair by non-homologous end-joining in DNA mismatch repair-deficient human colorectal cancer cell lines.
Jacob S; Miquel C; Sarasin A; Praz F
Nucleic Acids Res; 2005; 33(1):106-13. PubMed ID: 15642697
[TBL] [Abstract][Full Text] [Related]
10. The role of hMLH1, hMSH3, and hMSH6 defects in cisplatin and oxaliplatin resistance: correlation with replicative bypass of platinum-DNA adducts.
Vaisman A; Varchenko M; Umar A; Kunkel TA; Risinger JI; Barrett JC; Hamilton TC; Chaney SG
Cancer Res; 1998 Aug; 58(16):3579-85. PubMed ID: 9721864
[TBL] [Abstract][Full Text] [Related]
11. Role of mismatch repair in the induction of chromosomal aberrations and sister chromatid exchanges in cells treated with different chemotherapeutic agents.
Vernole P; Pepponi R; D'Atri S
Cancer Chemother Pharmacol; 2003 Sep; 52(3):185-92. PubMed ID: 12827294
[TBL] [Abstract][Full Text] [Related]
12. Analysis of microsatellite instability in acquired drug-resistance human tumor cell lines.
Picard SF; Franco N; Sergent C; Chauffert B; Lizard-Nacol S
Oncol Rep; 2002; 9(5):971-6. PubMed ID: 12168057
[TBL] [Abstract][Full Text] [Related]
13. Enhanced repair of a cisplatin-damaged reporter chloramphenicol-O-acetyltransferase gene and altered activities of DNA polymerases alpha and beta, and DNA ligase in cells of a human malignant glioma following in vivo cisplatin therapy.
Ali-Osman F; Berger MS; Rairkar A; Stein DE
J Cell Biochem; 1994 Jan; 54(1):11-9. PubMed ID: 8126081
[TBL] [Abstract][Full Text] [Related]
14. Decreased cisplatin damage-dependent DNA synthesis in cellular extracts of mismatch repair deficient cells.
Ferry KV; Fink D; Johnson SW; Nebel S; Hamilton TC; Howell SB
Biochem Pharmacol; 1999 Apr; 57(8):861-7. PubMed ID: 10086318
[TBL] [Abstract][Full Text] [Related]
15. Role of the DNA repair nucleases Rad13, Rad2 and Uve1 of Schizosaccharomyces pombe in mismatch correction.
Kunz C; Fleck O
J Mol Biol; 2001 Oct; 313(2):241-53. PubMed ID: 11800554
[TBL] [Abstract][Full Text] [Related]
16. DNA mismatch repair and p53 function are major determinants of the rate of development of cisplatin resistance.
Lin X; Howell SB
Mol Cancer Ther; 2006 May; 5(5):1239-47. PubMed ID: 16731756
[TBL] [Abstract][Full Text] [Related]
17. Induction of JNK and c-Abl signalling by cisplatin and oxaliplatin in mismatch repair-proficient and -deficient cells.
Nehmé A; Baskaran R; Nebel S; Fink D; Howell SB; Wang JY; Christen RD
Br J Cancer; 1999 Mar; 79(7-8):1104-10. PubMed ID: 10098743
[TBL] [Abstract][Full Text] [Related]
18. Antisense GADD45 expression results in decreased DNA repair and sensitizes cells to u.v.-irradiation or cisplatin.
Smith ML; Kontny HU; Zhan Q; Sreenath A; O'Connor PM; Fornace AJ
Oncogene; 1996 Nov; 13(10):2255-63. PubMed ID: 8950993
[TBL] [Abstract][Full Text] [Related]
19. Defining the function of XPC protein in psoralen and cisplatin-mediated DNA repair and mutagenesis.
Chen Z; Xu XS; Yang J; Wang G
Carcinogenesis; 2003 Jun; 24(6):1111-21. PubMed ID: 12807748
[TBL] [Abstract][Full Text] [Related]
20. Gene-specific repair of Pt/DNA lesions and induction of apoptosis by the oral platinum drug JM216 in three human ovarian carcinoma cell lines sensitive and resistant to cisplatin.
O'Neill CF; Koberle B; Masters JR; Kelland LR
Br J Cancer; 1999 Dec; 81(8):1294-303. PubMed ID: 10604725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]